Literature DB >> 7654127

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

D V Jeste1, M P Caligiuri, J S Paulsen, R K Heaton, J P Lacro, M J Harris, A Bailey, R L Fell, L A McAdams.   

Abstract

BACKGROUND: Neuroleptic-induced tardive dyskinesia (TD) is a major iatrogenic disorder that is more prevalent among older patients. The objective of this study was to determine the incidence of and risk factors for TD in neuroleptic-treated patients over age 45 years.
METHODS: We studied 266 middle-aged and elderly outpatients with a median duration of 21 days of total lifetime neuroleptic exposure at study entry. Most patients were treated throughout the study with either a high-potency or a low-potency neuroleptic and maintained on relatively low doses. The patients were followed up at 1- to 3-month intervals with "blind" assessment of psychopathologic condition, clinically as well as instrumentally (ie, using electromechanical sensors with computerized data reduction, including spectral analysis) evaluated movement disorder, and global cognitive function.
RESULTS: Cumulative incidence of TD was 26%, 52%, and 60% after 1, 2, and 3 years, respectively. The principal risk factors for TD were duration of prior neuroleptic use at baseline, cumulative amount of high-potency neuroleptics, history of alcohol abuse/dependence, borderline or minimal dyskinesia, and tremor on instrumental assessment.
CONCLUSION: Use of higher amounts of neuroleptics, particularly high-potency ones, should be avoided in older patients, patients with alcohol abuse/dependence, or patients with a subtle movement disorder at baseline; these patients are at a higher risk of developing TD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654127     DOI: 10.1001/archpsyc.1995.03950210050010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  44 in total

Review 1.  Late-onset schizophrenia: epidemiology, diagnosis, management and outcomes.

Authors:  P A Wynn Owen; D J Castle
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 2.  Oxidative mechanisms and tardive dyskinesia.

Authors:  James B Lohr; Ronald Kuczenski; Alexander B Niculescu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Antipsychotic treatment for late-life schizophrenia.

Authors:  Jeremy A Sable; Dilip V Jeste
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

Review 4.  Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?

Authors:  Nathan Herrmann; Krista L Lanctôt
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects.

Authors:  Gary Remington; Margaret Hahn
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

6.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

Review 8.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

9.  Segmental Dystonia in the Context of Dextromethorphan Abuse: A New Cause of Delayed Onset Drug-Induced Dystonia?

Authors:  Thomas E Kimber; Philip D Thompson
Journal:  Mov Disord Clin Pract       Date:  2015-03-28

Review 10.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.